Celgene Could Be the Best CAR-T Stock to Buy, Not Gilead Sciences
Gilead Sciences' (NASDAQ: GILD) recently approved Yescarta could be a billion-dollar blockbuster cancer-cell therapy, but the company could face stiff competition from Celgene (NASDAQ: CELG) someday. Celgene has successfully used research and development (R&D), acquisitions, and partnerships to become one of the world's biggest oncology biotech companies, and the use of this strategy could catapult it ahead of Gilead Sciences in chimeric antigen receptor T-cell therapy (CAR-T).
Celgene expects to report over $13 billion in sales this year from its lineup of top-selling drugs. If it hits that goal, it would represent 16% growth from 2016.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Gilead Sciences Inc Stock
€67.87
-0.410%
We see a rather positive sentiment for Gilead Sciences Inc with 11 Buy predictions and 1 Sell predictions.
With a target price of 85 € there is a positive potential of 25.24% for Gilead Sciences Inc compared to the current price of 67.87 €.
